IASIS PHARMA has launched a new pharmaceutical product under the brand name Lartokaz. It is an Irbesartan/hydrochlorothiazide combination preparation in two strengths: (150+12,5)mg/tab and (300+12,5)mg/tab respectively. Irbesartan is an angiotensin II receptor antagonist used mainly for the treatment of hypertension and in a combination formulation with hydrochlorothiazide(diuretic), is able to achieve an additive antihypertensive effect.
IASIS PHARMA has launched a new pharmaceutical product under the brand name Raberen (as rabeprazole sodium). Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. Raberen in either 10 or 20 mg form of gastro-resistant tablets, is the 1st generic rabeprazole, which has been successfully launched in the Greek pharmaceutical market by [...]
HYATT REGENCY HOTEL, THESSALONIKI, 12/04/2014 IASIS PHARMA participated, as it consistently does every year, in the Annual Spring Day Conference of the Hellenic Society of Dermatology and Venereology that took place at the HYATT REGENCY HOTEL Thessaloniki, on 12 April 2014. IASIS PHARMA stand was visited by a high number of Dermatologists where three (3) of its [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name Contrahist (as levocetirizine dihydrochloride). It is a non-sedative antihistamine and is available as 5 mg-strength f.c tablets and a 0.5 mg/mL oral solution. Contrahist is the 1st generic levocetirizine, which has been successfully launched in the Greek pharmaceutical market by a Greek pharmaceutical [...]
BIOMEDICAL RESEARCH FOUNDATION AMPITHEATRE, ATHENS, 15/03/2014 IASIS PHARMA successfully participated in the 19th Hellenic Conference for Helicobacter Pylori and Other Infections of the Peptic System that took place at the amphitheater of the Biomedical research Foundation, Athens, 15 March 2014, organized by the Hellenic Society for the Study of H pylori. Congress invitees included distinguished gastroenterologists [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name Licepler (Eplerenone). Licepler is specifically indicated for the reduction of risk of cardiovascular death in people with heart failure and left ventricular dysfunction ≤40% after a recent acute myocardial infarction, in combination with standard therapies and as treatment against hypertension. Licepler (25mg/f.c. tab [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name Venlaxin. The active ingredient of Venlaxin is venlafaxine, approved for the treatment of MajorDepressive Disorder. Venlaxin prolonged release tablets (PR tabs) utilize a unique osmotic tablet technology to specifically address the once daily delivery of the drug. This unique osmotic tablet technology allows [...]
IASIS PHARMA has launched a new pharmaceutical product under the brand name Avalsan plus. Avalsan plus film-coated tablets contain two active substances namely, valsartan and hydrochlorothiazide in the following strengths: (80+12,5)mg/tab and (160+25)mg/tab. Both substances help to control high blood pressure (hypertension). Avalsan plus is used to treat high blood pressure which is not adequately [...]
DIVANI CARAVEL HOTEL, ATHENS, 14/12/2013 IASIS PHARMA participated, as it consistently does every year, in the Annual Winter Day Conference of the Hellenic Society of Dermatology and Venereology that took place at the DIVANI CARAVEL HOTEL, in Athens, on 14 December 2013. IASIS PHARMA stand was visited by a high number of Dermatologists where three (3) [...]
MAKEDONIA PALACE HOTEL, THESSALONIKI, 05-07/12/2013 ΙΑSIS PHARMA successfully participated in the 33ο Hellenic Congress of Gastroenterology under the auspices of the of the Hellenic Society of Gastroenterology at the MAKEDONIA PALACE HOTEL, Thessaloniki, 5-7 December 2013. The main objective of the Congress was the presentation of the latest developments from the specialty in Greece and the [...]
